Apontis Pharma AG
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Apontis Pharma AG is a leading pharmaceutical company in Germany specializing in the development, marketing, and distribution of "Single Pills." These are fixed-dose combination drugs that integrate two to three active ingredients into a single tablet, primarily for treating cardiovascular diseases and other chronic conditions. The company's core strategy is to simplify medication regimens to improve patient adherence and therapeutic outcomes. Apontis Pharma maintains a broad portfolio of proprietary products and collaborates on strategic partnerships, leveraging its established access to a network of approximately 23,500 physicians to promote its offerings and provide related consulting and training services.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Apontis Pharma AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-13 10:30 |
M&A Activity
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
|
English | 7.2 KB | |
| 2025-05-15 07:30 |
Earnings Release
APONTIS PHARMA publishes results for the first quarter of 2025 and confirms for…
|
English | 25.5 KB | |
| 2025-03-31 14:00 |
Earnings Release
APONTIS PHARMA with significant sales and earnings increase in 2024 financial y…
|
English | 26.3 KB | |
| 2025-03-31 00:00 |
Annual Report
Annual financial statements 2024
|
English | 1.3 MB | |
| 2025-03-06 20:50 |
M&A Activity
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | |
| 2025-03-05 20:50 |
M&A Activity
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
|
English | 7.6 KB | |
| 2024-12-23 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 27.9 KB | |
| 2024-12-12 14:42 |
Director's Dealing
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | |
| 2024-12-11 16:00 |
Director's Dealing
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
|
English | 7.7 KB | |
| 2024-12-10 10:35 |
Director's Dealing
APONTIS PHARMA AG: Thomas Zimmermann, sell
|
English | 7.5 KB | |
| 2024-11-27 00:00 |
Board/Management Information
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 398.4 KB | |
| 2024-11-22 11:30 |
M&A Activity
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB | |
| 2024-11-21 11:30 |
M&A Activity
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
|
English | 14.2 KB | |
| 2024-11-07 07:30 |
Earnings Release
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations i…
|
English | 40.7 KB | |
| 2024-10-30 16:20 |
M&A Activity
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting…
|
English | 13.9 KB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
